First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease
James Ferrero, et al.
Abstract
Introduction
Aducanumab (BIIB037), a human monoclonal antibody selective for aggregated forms of amyloid beta, is being investigated as a disease-modifying treatment for Alzheimer's disease (AD).
Methods
This randomized, double-blind, placebo-controlled single ascending-dose study investigated the safety, tolerability, and pharmacokinetics (PK) of aducanumab in patients with mild-to-moderate AD. Eligible patients were sequentially randomized 6:2 to aducanumab (0.3, 1, 3, 10, 20, 30, and 60 mg/kg) or placebo.
Results
The primary outcome was safety and tolerability. Doses ≤30 mg/kg were generally well tolerated with no severe or serious adverse events (SAEs). All three patients who received 60-mg/kg aducanumab developed SAEs of symptomatic amyloid-related imaging abnormalities, which completely resolved by weeks 8–15. Aducanumab Cmax, AUC0–last, and AUCinf increased in a dose-proportional manner.
Discussion
In this single-dose study, aducanumab demonstrated an acceptable safety and tolerability profile and linear PK at doses ≤30 mg/kg (clinicaltrials.gov NCT01397539).
"Although there was an increase in plasma levels of Ab40 and Ab42 at 60 mg/kg, aducanumab did not appear
to significantly affect plasma levels of Ab40 or Ab42 at the lower doses (0.3 mg/kg to 30 mg/kg). The largely unaffected soluble Ab levels are consistent with the very low affinity of aducanumab for soluble monomeric Ab. At 60 mg/kg, both Ab40 and Ab42 also demonstrated higher baseline/pre-dose values and higher patient variability than the lower dose cohort patients, thus complicating the interpretation. No dose-dependent response was observed for change in mean ADAS-Cog 13 scores after single-dose administration of aducanumab."
- Forums
- ASX - By Stock
- ATH
- Biogen Paper
Biogen Paper
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ATH (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.5¢ |
Change
0.001(25.0%) |
Mkt cap ! $26.19M |
Open | High | Low | Value | Volume |
0.5¢ | 0.5¢ | 0.5¢ | $27.94K | 6.050M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
47 | 58163299 | 0.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.5¢ | 57489001 | 48 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
47 | 58163299 | 0.004 |
75 | 84508146 | 0.003 |
19 | 29345125 | 0.002 |
16 | 81865102 | 0.001 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.005 | 57455001 | 47 |
0.006 | 17905330 | 28 |
0.007 | 9788861 | 19 |
0.008 | 8393109 | 16 |
0.009 | 4646078 | 9 |
Last trade - 16.10pm 28/03/2024 (20 minute delay) ? |
|
|||||
Last
0.5¢ |
  |
Change
0.001 ( 0.00 %) |
|||
Open | High | Low | Volume | ||
0.5¢ | 0.5¢ | 0.5¢ | 20524121 | ||
Last updated 15.46pm 28/03/2024 ? |
Featured News
ATH (ASX) Chart |
The Watchlist
BGD
BARTON GOLD HOLDINGS LIMITED
Alex Scanlon, Managing Director & CEO
Alex Scanlon
Managing Director & CEO
SPONSORED BY The Market Online